IHC - diagnostic panel for Hodgkin's Lymphoma

The IHC panel for Hodgkin's Lymphoma is used to confirm the diagnosis of Hodgkin's lymphoma and differentiate it from other similar conditions. It also helps to define the subtype of Hodgkin's lymphoma, which can guide treatment options.

No, fasting is not required for this test. It is performed on a tissue sample obtained through a biopsy.

A biopsy of the suspected lymph node or other affected tissue is taken by your healthcare provider. This is usually done under local or general anesthesia.

Each marker has a specific meaning. For instance, CD15 and CD30 are usually positive in classic Hodgkin's lymphoma. Other markers like EBV, CD20, PAX5, and LCA can help differentiate it from non-Hodgkin's lymphoma. Markers like CD3, CD5, CD4, CD57, Oct2, BOB1, and ALK-1 can also assist in identifying different subtypes or ruling out other conditions.

The turnaround time is typically 5-7 days but may vary depending on the laboratory.

There is no specific preparation needed for this test. However, because a biopsy is involved, your healthcare provider will give you instructions based on your general health, the location of the biopsy, and the type of anesthesia used.

This test is done when Hodgkin's lymphoma is suspected based on clinical symptoms, physical examination, and other preliminary tests.

The IHC panel for Hodgkin's lymphoma can provide critical information about the type and stage of the lymphoma, which is essential for determining the best treatment strategy.

This test is typically performed once to establish a diagnosis. However, if treatment is given and then symptoms reappear, the test may be repeated.

In a normal lymph node, there is a specific pattern of marker expression. Any significant deviation from this pattern, like the increased presence of CD15 or CD30, can indicate Hodgkin's lymphoma.

The primary precaution is related to the biopsy procedure. Your healthcare provider will give you specific instructions based on your overall health and the location of the biopsy.

Non-modifiable factors include genetic predisposition to Hodgkin's lymphoma. Modifiable factors are limited as these markers are specific to the cells and not influenced by lifestyle or environmental factors.

If results are abnormal, you should consult with your hematologist or oncologist. They will interpret the results in the context of your overall health and symptoms and recommend the next steps.

Other tests might include complete blood count (CBC), blood chemistry tests, imaging tests (like CT, PET, or MRI scans), bone marrow biopsy, and genetic testing.

The results are usually reliable, but like any test, there may be a chance of false positives or negatives. The results should always be interpreted in conjunction with your symptoms, history, and other test results.

In conclusion, the IHC panel for Hodgkin's lymphoma is a powerful diagnostic tool. It provides essential insights into the nature and type of lymphoma, guiding the path for precise treatment. As with any test, ensure that you discuss the results with your healthcare provider to understand what they mean for your health and treatment plan.